virus
small
infecti
organ
oblig
intracellular
parasit
found
virtual
ecosystem
number
million
within
last
year
etiolog
mechan
notori
virus
affect
human
describ
virus
enclos
structur
code
protein
coat
along
either
dna
rna
genom
genet
materi
dna
rna
virus
contain
inform
need
replic
make
number
copi
viru
virus
consid
genet
mobil
element
mainli
cellular
origin
identifi
extend
coevolut
host
viru
special
host
cell
provid
complex
biosynthet
metabol
machineri
prokaryot
eukaryot
organ
help
propag
virus
whole
viru
particl
known
virion
viral
infect
abil
spread
man
man
sourc
man
either
indirect
direct
contact
particularli
mean
excret
matter
contamin
articl
throat
nose
secret
common
droplet
infect
insect
vector
also
spread
infect
eg
transmiss
dengu
fever
mosquito
aed
aegypti
number
viral
diseas
transmit
milk
water
eg
infecti
hepat
poliomyel
sometim
virus
chang
function
cell
without
destroy
host
cell
virus
might
remain
dormant
period
time
multipli
viral
infect
lifelong
immun
confer
one
attack
diseas
small
pox
measl
mump
wherea
case
common
cold
shortdur
immun
produc
attack
viral
diseas
mode
artifici
immun
similar
bacteri
infect
passiv
immun
dead
live
vaccin
use
bring
activ
immun
diagnost
prospect
laboratorybas
surveil
princip
signific
manag
earli
detect
emerg
reemerg
infecti
diseas
within
past
year
mani
techniqu
develop
diagnos
viral
infect
procedur
includ
detect
viral
antigen
lesion
fluoresc
antibodi
techniqu
microscop
examin
lesion
perform
serolog
test
cours
infect
skin
test
techniqu
identif
isol
viru
virus
pathogen
human
broadli
classifi
accord
differ
region
bodi
mostli
affect
clinic
natur
infect
diseas
produc
tabl
simpl
classif
system
virus
follow
l
neurotrop
virus
virus
affect
central
nervou
system
eg
virus
rabi
poliomyel
influenza
contagi
respiratori
infect
caus
influenza
viru
commonli
known
flu
common
symptom
high
fever
cough
sneez
runni
nose
headach
sore
throat
muscl
ach
myalgia
gener
feel
ill
malais
earli
stage
infect
symptom
flu
similar
common
cold
commonli
confus
common
cold
howev
much
sever
diseas
seriou
condit
influenza
lead
pneumonia
could
fatal
significantli
young
children
elderli
howev
nausea
vomit
produc
especi
children
mistaken
gastroenter
stomach
flu
typic
influenza
spread
air
cough
sneez
infect
bird
drop
addit
also
transmit
direct
contact
viruscontamin
surfac
bodi
fluid
saliva
nasal
secret
fece
blood
year
world
popul
affect
season
epidem
influenza
season
influenza
epidem
occur
everi
year
northern
southern
hemispher
mainli
winter
howev
tropic
countri
influenza
occur
throughout
year
accord
world
health
organ
annual
pandem
lead
million
case
seriou
ill
death
unvaccin
children
infect
year
death
occur
mostli
young
old
health
problem
antigen
shift
lead
emerg
new
differ
influenza
viru
may
caus
influenza
pandem
pandem
less
frequent
result
larger
outbreak
centuri
three
influenza
epidem
occur
spanish
influenza
basi
surfac
antigen
four
genera
famili
type
b
c
thogotoviru
influenza
b
predomin
pathogen
season
influenza
influenza
viru
sever
influenza
viru
b
may
caus
sever
influenza
influenza
type
c
infect
gener
respons
mild
respiratori
ill
could
caus
epidem
influenza
virus
mainli
affect
cattl
found
infest
human
caus
ill
type
influenza
danger
known
caus
outbreak
diseas
wild
bird
repres
natur
host
virus
virus
infect
anim
bird
pig
hors
influenza
virus
subdivid
number
subtyp
base
composit
hemagglutinin
ha
neuraminidas
na
protein
differ
hemagglutinin
subtyp
differ
neuraminidas
subtyp
respect
exist
far
type
flu
viru
continu
chang
gener
caus
larg
flu
pandem
howev
influenza
b
virus
respons
pandem
mutat
influenza
virus
result
number
differ
influenza
subtyp
strain
common
influenza
viru
specif
varieti
viru
gener
name
accord
host
origin
geograph
locat
strain
number
year
isol
influenza
b
infect
occur
human
divid
subtyp
broken
lineag
strain
current
circul
influenza
b
virus
belong
one
two
lineag
byamagata
bvictoria
influenza
type
c
infect
caus
mild
respiratori
ill
compar
common
respiratori
virus
nearli
adult
infect
influenza
c
viru
howev
milder
rare
either
type
b
caus
epidem
structur
influenza
c
virus
differ
comparison
influenza
b
genera
c
virion
hexagon
structur
surfac
form
stretch
cordlik
structur
influenza
c
virus
seven
rna
segment
influenza
b
contain
eight
rna
segment
influenza
seriou
infecti
diseas
danger
deadli
specif
young
one
elderli
weak
immun
patient
invent
modern
vaccin
mortal
rate
due
flu
viru
consider
decreas
chanc
recurr
infest
vaccin
accompani
emerg
new
antiinfluenza
agent
necessari
fight
season
pervas
influenza
strain
nowaday
import
given
design
inhibit
agent
influenza
neuraminidas
prove
appropri
medicin
prophylaxi
influenza
infect
therapi
till
four
medicin
accept
food
drug
administr
fda
cure
influenza
ailment
two
drug
grown
resist
influenza
strain
henc
applic
therefor
numer
chanc
area
develop
antivir
therapi
two
recent
drug
mechan
inhibit
influenza
viru
proton
channel
involv
procedur
liber
viru
particl
infect
host
cell
neuraminidas
na
enzym
work
basi
viral
recognit
entri
host
cell
current
neuraminidas
inhibitor
frequent
use
fdaapprov
treatment
influenza
viru
appli
effect
develop
resist
yet
within
viru
oseltamivir
zanamivir
drug
function
affect
activ
neuraminidas
na
protein
viru
neuraminidas
enzym
oper
basi
cleav
host
cell
sialic
acid
residu
viral
hemagglutinin
turn
releas
new
virus
carri
forward
infect
healthi
cell
viral
neuraminidas
catalyt
site
highli
specif
influenza
b
virus
drug
oseltamivir
zanamivir
serv
stabl
transform
state
counterpart
sialosyl
cation
unstabl
transform
state
complex
enzymat
procedur
viral
sialidas
neuraminidas
inhibitor
drug
similar
enough
structur
sialosyl
cation
transit
state
complex
allow
attach
tightli
sialic
acid
activ
site
obstruct
viral
bud
howev
constant
develop
drugresist
influenza
strain
enhanc
need
continu
research
innov
technolog
product
new
drug
improv
antivir
mechan
safeti
enhanc
toler
eight
drug
accept
cure
influenza
viru
infect
april
drug
could
classifi
neuraminidas
inhibitor
eg
oseltamivir
zanamivir
peramivir
laninamivir
octano
matrix
inhibitor
eg
rimantadin
amantadin
polymeras
inhibitor
favipiravir
ribavirin
amantadin
approv
first
antivir
compound
treatment
wide
distribut
influenza
viru
infect
compound
abil
block
transfer
h
ion
help
matrix
protein
medium
inner
portion
viral
particl
henc
prevent
disassembl
influenza
viru
molecul
insid
endosom
amantadin
rimantadin
approv
adult
patient
abl
prevent
treat
reduc
sever
influenza
viru
infest
children
older
one
preval
resist
also
lead
abandon
amantadin
medic
influenza
infect
howev
interest
grow
applic
amantadin
evidenti
therapi
parkinson
diseas
levodopainduc
dyskinesia
although
clinic
research
necessari
explor
new
applic
zanamivir
distinct
potent
inhibitor
neuraminidas
protein
influenza
b
viru
prevent
influenza
infect
affect
releas
viru
zanamivir
appli
inhal
also
accompani
oseltamivir
ingest
oral
rout
accord
mani
research
oral
oseltamivir
inhal
zanamivir
prove
net
benefit
control
death
rate
sever
influenza
symptom
complic
two
neuraminidas
inhibitor
introduc
therapi
influenza
infect
success
zanamivir
oseltamivir
first
peramivir
could
administ
intraven
inject
laninamivir
octano
found
effect
administ
inhal
notabl
peramivir
found
clinic
potenc
equal
oseltamivir
cure
sever
season
influenza
efficaci
laninamivir
octano
found
treatment
season
influenza
well
oseltamivirresist
viru
adult
peramivir
laninamivir
effect
use
onedos
therapi
influenza
b
virus
applic
bound
countri
ribavirin
also
known
virazol
report
first
synthet
nucleosid
analogu
activ
toward
broad
spectrum
rna
virus
rsv
hcv
influenza
viru
found
broadest
spectrum
antivir
agent
ever
report
synthet
materi
induc
interferon
chief
mechan
drug
action
includ
inhibit
imp
dehydrogenas
help
convers
imp
xanthosin
monophosph
thu
respons
product
gtp
ribavirin
inhibit
imp
dehydrogenas
henc
possess
immunosuppress
activ
lead
remark
success
ribavirin
therapi
hcv
infest
accompani
peginterferon
patient
hcv
infect
undergo
therapi
telaprevir
peginterferon
ribavirin
found
outstand
level
respons
viru
ribavirin
effect
hinder
rna
polymeras
influenza
viru
triphosph
form
apart
ribavirin
could
also
use
treatment
lassa
fever
hemorrhag
fever
viru
infect
ribavirin
yet
got
formal
licens
medic
effect
ribavirin
rna
virus
also
found
potenti
effect
mani
infecti
diseas
dengu
viru
noroviru
hendra
nipah
virus
marburg
viru
howev
clinic
evid
still
necessari
prove
new
applic
favipiravir
chemic
structur
carboxamid
chiefli
introduc
therapi
influenza
viru
infect
favipiravir
invent
approv
japan
could
effect
use
treatment
influenza
b
c
viru
infect
importantli
favipiravir
triphosph
broadspectrum
antivir
agent
show
inhibitori
activ
rna
polymeras
present
influenza
virus
highli
pathogen
virus
mani
positiveand
negativesens
rna
virus
also
belong
group
influenza
viru
henc
favipiravir
activ
recent
favipiravir
found
effect
cure
patient
infect
ebola
viru
ebov
also
inhibit
growth
human
noroviru
human
arena
virus
machupo
junin
pichind
virus
new
applic
need
extens
research
clinic
trial
plant
foundat
element
mani
medicin
structur
applic
today
drug
prescrib
either
directli
extract
plant
deriv
product
result
plant
antivir
extract
natur
origin
found
possess
pharmacolog
pharmaceut
properti
use
differ
medicin
plant
combin
therapi
prove
effect
numer
virus
hsv
influenza
virus
mani
plant
extract
observ
broad
spectrum
antivir
activ
exampl
ocimum
basilicum
agrimonia
pilosa
potent
wide
rang
rna
dna
virus
mani
phytochem
may
also
dosedepend
viral
inhibit
moreov
resolv
import
issu
drug
resist
gener
synthet
drug
eg
plantderiv
product
polyciton
function
resist
strain
hiv
plantderiv
product
also
inexpens
could
easili
access
differ
part
world
natur
product
even
found
less
toxic
cheaper
impart
side
effect
comparison
synthet
drug
apart
prove
wide
therapeut
benefit
differ
type
condit
plantderiv
ingredi
shown
differ
kind
mechan
activ
virus
enhanc
defens
immun
reaction
one
import
mechan
antivir
treatment
mani
recent
regist
product
work
immun
boost
procedur
toward
viral
infect
interleukin
colonystimul
factor
interferon
wellknown
immunostimul
interferon
deriv
polypeptid
glycoprotein
act
catalyst
enhanc
growth
certain
peculiar
enzym
control
viral
reconstruct
cell
interleukin
factor
increas
activ
develop
distinct
progress
guidanc
immun
cell
abl
nullifi
viru
similarli
colonystimul
factor
regul
prolifer
distinct
progenitor
cell
white
blood
cell
lineag
howev
mani
drug
ribavirin
also
affect
posit
immun
respons
mani
natur
materi
research
immunomodulatori
activ
carbohydr
stilbenoid
alkaloid
polyphenol
lectin
peptid
plant
sourc
chief
categori
drug
could
use
immunomodul
anoth
import
target
antivir
therapi
adjunct
viru
host
cell
entranc
entri
viru
occur
cell
interact
either
singl
cell
surfac
receptor
certain
coreceptor
viral
envelop
get
fuse
host
cell
membran
intrud
cell
viru
dismantl
releas
genom
mani
approv
drug
affect
procedur
viral
infect
eg
tromantadin
treatment
hsv
infect
chang
glycoprotein
present
surfac
host
cell
stop
adhes
intrus
uncoat
viru
studi
differ
plantderiv
materi
shown
similar
mechan
prevent
viral
growth
eg
plant
lectin
extract
genera
hippeastrum
galanthu
shown
inhibit
activ
hivspecif
glycoprotein
thu
result
inhibit
entranc
viru
cell
categori
plant
materi
includ
galactos
glucos
nacetylgalactosamin
found
contain
antivir
action
sever
acut
respiratori
syndrom
corona
viru
sarscov
felin
infecti
periton
viru
factor
also
inhibit
viral
adhes
host
cell
mani
natur
agent
also
work
influenza
viru
receptor
attach
merg
protein
ie
hemagglutinin
mani
studi
retard
viru
dismantl
emerg
genet
matter
cell
done
extract
deriv
variou
seawe
heparin
sulfat
molecul
extract
carrageenan
seawe
also
shown
employ
antivir
activ
toward
dengu
viru
arrest
uncoat
viru
host
cell
viral
arrang
mutat
process
next
import
mechan
antivir
polici
genom
could
manag
earlier
util
cellular
machineri
benefit
rna
virus
could
directli
integr
host
genom
dna
virus
revers
transcript
integr
replic
transcript
translat
potenti
step
procedur
coumarin
also
known
calanolid
extract
chiefli
calophyllum
lanigerum
belong
emin
categori
plantderiv
antivir
found
irrevers
bind
activ
site
revers
transcriptas
enzym
larg
quantiti
calanolid
could
extract
latex
relev
speci
plant
calanolid
also
chosen
phase
ii
clinic
studi
antiretrovir
treatment
shown
synergist
effect
current
approv
drug
bevirimat
extract
obtain
chines
herb
syzygium
claviflorum
found
matur
inhibit
capabl
proteas
inhibitor
compound
possess
abil
suppress
cleavag
gag
polyprotein
hiv
henc
structur
enzymat
protein
form
anoth
chines
prepar
chingfangpaitusan
consum
tradit
herbal
decoct
contain
quercetin
isoquercetin
chaihu
compound
stop
influenza
viru
replic
interrupt
intracellular
protein
process
transport
bud
properti
shikim
acid
chemic
formula
acid
organ
compound
found
natur
import
link
pathway
develop
aromat
amino
acid
lignin
variou
alkaloid
present
plant
microorgan
shikim
acid
primari
progenitor
pharmaceut
manufactur
antiinfluenza
drug
oseltamivir
oseltamivir
market
brand
name
tamiflu
potenti
antivir
medicin
use
cure
prevent
influenza
influenza
b
infect
mode
applic
mouth
either
form
pill
liquid
oseltamivir
first
neuraminidas
inhibitor
avail
oral
approv
medic
use
found
complementari
list
world
health
organ
list
essenti
medicin
indic
lower
costebenefit
ratio
gener
version
approv
unit
state
oseltamivir
compound
act
neuraminidas
inhibitor
potenti
inhibitor
influenza
neuraminidas
enzym
neuraminidas
inhibitor
nai
defin
class
drug
stop
block
activ
neuraminidas
enzym
henc
gener
util
antivir
medicin
inhibit
action
viral
neuraminidas
present
influenza
virus
prevent
reproduct
bud
host
cell
enzym
respons
cleav
sialic
acid
present
glycoprotein
surfac
human
cell
turn
help
new
virion
come
cell
oseltamivir
inhibit
function
neuraminidas
protein
prevent
new
viral
particl
releas
viru
leav
cell
infect
cell
eventu
viru
die
isol
shikim
acid
fruit
illicium
religiosum
primarili
report
ekmann
name
shikim
acid
deriv
orient
plant
shikiminoki
japanes
shikim
acid
avail
quantiti
extract
fruit
illicium
verum
chines
star
anis
recent
report
liquidambar
styraciflua
commonli
known
sweetgum
tree
could
renew
sourc
shikim
acid
fact
shown
sweetgum
tree
yield
shikim
acid
amount
compar
verum
seed
annual
fruit
plant
shikim
acid
isol
present
tabl
shikim
acid
obtain
star
anis
present
anion
form
shikim
cyclohexanecarboxyl
acid
cyclohexen
cyclitol
shikim
acid
form
follow
biosynthesi
pathway
describ
picea
pungen
branch
neish
picea
glauca
branch
neish
eucalyptu
sieberiana
cambium
hilli
eucalyptu
regnan
cambium
hilli
ginkgo
biloba
inner
bark
leav
hasegawa
tateoka
pinu
thunbergii
leav
hasegawa
tateoka
liquidambar
styraciflua
seed
enrich
et
al
phosphoenolpyruv
react
erythros
yield
dahp
presenc
catalyst
ie
enzym
dahp
synthas
dahp
chang
dhq
presenc
enzym
dhq
synthas
dhq
dehydr
acid
enzym
dehydratas
next
biosynthet
step
transform
shikim
acid
reduct
reaction
catalyz
shikim
dehydrogenas
nicotinamid
adenin
dinucleotid
phosphat
nadph
contribut
cofactor
reduct
reaction
shikim
acid
natur
compound
key
role
intermediari
substanc
manufactur
amino
acid
therefor
deriv
wide
spread
variou
plant
potenti
biolog
properti
apart
shikim
acid
pharmacolog
relev
also
act
intermedi
manufactur
mani
drug
mostli
relat
antivir
agent
call
oseltamivir
tamiflu
common
method
synthesi
racem
sa
obtain
diel
alder
reaction
method
acryl
acid
use
start
materi
sa
synthesi
yield
studi
also
report
sa
synthes
quinic
acid
obtain
cinchona
bark
grew
hinrich
also
report
synthesi
sa
achiev
overal
yield
koreeda
ciufolini
achiev
higher
yield
overal
yield
among
highest
yield
found
synthesi
fleme
oxid
sa
first
isol
microbi
sourc
escherichia
coli
millcan
also
report
bacillu
speci
increas
yield
sa
initi
activ
shikim
dehydrogenas
shikim
kinas
enzym
strain
e
coli
e
coli
yield
gl
cultur
yield
signific
amount
sa
increas
activ
kinas
ii
enzym
synthesi
sa
adachi
et
al
introduc
novel
method
enzymat
synthesi
shikim
acid
quinic
acid
help
dri
cell
membran
portion
gluconobact
oxydan
ifo
enzym
obtain
quinat
dehydrogenas
dehydratas
util
transform
quinic
acid
dehydroshikim
treat
nadphdepend
dglucos
dehydrogenas
shikim
dehydrogenas
obtain
shikim
acid
techniqu
suitabl
laboratori
recoveri
shikim
acid
perspect
industri
product
shikim
acid
pathway
biosynthet
pathway
absent
mammal
involv
metabol
carbohydr
allow
biosynthesi
aromat
amino
acid
aromat
compound
naphthoquinon
ubiquinon
folat
shikim
pathway
part
metabol
occur
plant
microorgan
microbi
eukaryot
bacteria
parasit
sequenc
sevenstep
shikim
pathway
consist
transform
phosphoenolpyruv
start
condens
condens
cycliz
lead
synthesi
chorism
acid
activ
form
coenzym
coa
lead
format
phenol
compound
turn
boxid
chang
acid
benzoic
acid
seri
gallic
protocatechu
etc
gallic
acid
combin
simpl
sugar
transform
tannin
compound
gallic
ellag
tannin
addit
molecul
phosphoenolpyruv
addit
intermedi
stage
lead
format
aromat
amino
acid
tyrosin
phenylalanin
amino
acid
pathway
includ
variou
enzym
synthas
synthas
shikim
dehydrogenas
shikim
kinas
dehydratas
chorism
synthas
shikim
acid
intermedi
product
biolog
pathway
shikim
dehydrogenas
facilit
revers
transform
reduct
shikim
shikim
acid
pathway
provid
new
methodolog
develop
new
herbicid
herbicideresist
crop
also
provid
opportun
engin
new
antibiot
antiparasit
drug
interrupt
action
enzym
henc
variou
import
research
carri
explor
pathway
illicium
genu
basic
sourc
shikim
acid
acid
discov
fruit
techniqu
constantli
improv
isol
shikim
acid
plant
fruit
adam
et
al
extract
shikim
acid
puriti
yield
base
dri
fruit
weight
obtain
help
soxhlet
extractor
h
extract
subsequ
purif
solkafloc
anion
exchang
resin
g
illicium
anisatum
seed
adam
method
modifi
simplifi
payn
edmond
improv
yield
shikim
acid
dri
basi
method
g
anisatum
seed
ground
dust
extract
soxhlet
extractor
ethanol
solvent
approxim
h
extract
treat
water
drop
formaldehyd
solut
obtain
orang
clear
solut
pass
anion
exchang
column
amberlit
acet
form
dri
weight
g
shikim
acid
elut
acet
acid
yellow
eluent
collect
heat
methanol
activ
carbon
recrystal
toluen
yield
brilliant
white
crystallin
substanc
modifi
adam
payn
method
exploit
china
industri
product
shikim
acid
illicium
genu
plant
weinstein
et
al
firstli
isol
high
puriti
shikim
acid
ginkgo
biloba
l
conduct
experi
studi
metabol
plant
especi
studi
shikim
pathway
purpos
plant
kept
metabol
atmospher
radioact
carbon
dioxid
sever
day
extract
plant
materi
done
ethanol
water
impur
extract
remov
pass
dowex
form
column
column
dowex
acet
form
use
pass
eluat
excel
separ
shikim
quinic
acid
achiev
gradual
elut
aqueou
acet
acid
suffici
pure
compound
found
final
passag
dowex
column
g
shikim
acid
g
quinic
acid
yield
g
fresh
leav
g
biloba
l
known
yield
shikim
acid
less
base
wet
leav
chromatograph
purif
high
loss
shikim
acid
occur
henc
techniqu
gave
extrem
low
yield
modifi
techniqu
employ
underhil
et
al
ginkgo
rose
shoot
grown
radioact
atmospher
yield
higher
content
shikim
acid
dri
basi
ginkgo
leav
case
use
ginkgo
techniqu
import
perspect
research
could
use
industriallevel
product
shikim
acid
multistag
process
result
high
product
loss
effici
method
isol
shikim
acid
leav
plant
liquidambar
genu
develop
li
et
al
process
fruit
coat
leav
liquidambar
genu
tree
dri
c
mill
soak
deioniz
water
h
subsequ
three
time
extract
pass
amberlit
acet
form
shikim
acid
elut
acet
acid
concentr
crystal
mix
ethyl
acet
methanol
shikim
acid
obtain
puriti
yield
depend
origin
content
shikim
acid
liquidambar
fruit
leav
approxim
dri
basi
depend
speci
abovedescrib
method
activ
exploit
chines
industri
product
shikim
acid
liquidambar
genu
plant
discuss
oseltamivir
commerci
trade
name
tamiflu
antivir
drug
synthes
shikim
acid
oseltamivir
help
lower
rate
spread
influenza
flu
viru
among
cell
bodi
interrupt
remov
viru
host
cell
drug
ingest
oral
capsul
form
suspens
influenza
viru
influenza
b
viru
may
treat
ingest
oseltamivir
firstli
act
like
inact
chemic
prodrug
chang
activ
state
metabol
process
insid
liver
hydroxyl
chang
activ
metabolitedth
free
carboxyl
oseltamivir
firstli
use
oral
activ
neuraminidas
inhibitor
serv
competit
inhibitor
action
viral
neuraminidas
na
enzym
sialic
acid
present
glycoprotein
found
surfac
normal
host
cell
hinder
activ
enzym
oseltamivir
stop
new
viral
particl
form
infect
cell
oseltamivir
indic
treatment
prevent
infect
due
influenza
b
virus
gastrointestin
tract
approxim
bioavail
oseltamivir
phosphat
made
readili
absorb
cell
consequ
oseltamivir
well
distribut
ingest
pill
nasal
mucosa
tracheal
line
tissu
middl
ear
elimin
oseltamivir
carboxyl
bodi
follow
rout
elimin
glomerular
filtrat
renal
tubular
excret
without
undergo
metabol
process
estim
averag
halflif
elimin
adult
rang
h
influenza
b
two
import
virus
respons
yearli
flu
season
human
be
name
basi
major
type
antigen
protein
present
viral
coat
antigen
protein
hemagglutinin
ha
neuraminidas
na
na
primari
target
oseltamivir
zanamivir
despit
rapid
growth
pharmaceut
biotechnolog
approach
develop
effect
antivir
therapi
still
challeng
influenza
creat
global
menac
societi
yet
develop
appropri
technolog
manag
epidem
resist
strain
apart
emerg
drug
resist
develop
mutant
strain
viru
introduct
virul
strain
expens
avail
drug
time
laps
vaccin
manufactur
mass
mortal
caus
difficult
problem
scenario
counterpart
altern
medicin
offer
huge
possibl
help
patient
herb
possess
wide
array
biolog
action
could
effici
exploit
manag
pandem
flu
nutrit
botan
properti
togeth
respons
provid
potent
tool
control
differ
type
viral
infect
access
wide
array
herb
constitu
potenti
activ
phytochem
increas
effect
antiinfluenza
agent
could
import
role
ongo
research
toward
novel
infect
shikim
acid
also
found
potenti
antivir
sourc
could
use
precursor
industri
product
antivir
oseltamivir
tamiflu
potent
viral
neuraminidas
inhibitor
rigor
research
optim
shikim
acid
product
util
bring
revolutionari
chang
antivir
therapi
